NEXICLON XR

Peak

clonidine

NDAORALTABLET, EXTENDED RELEASE
Approved
Dec 2009
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
2

Mechanism of Action

Adrenergic alpha2-Agonists

Pharmacologic Class:

Central alpha-2 Adrenergic Agonist

Clinical Trials (2)

NCT02096744Phase 1Completed

Bioequivalence of Two Transdermal Clonidine Administrations in Healthy Volunteers

Started Mar 2014
56 enrolled
Healthy
NCT00370838Phase 4Completed

Comparison of Keppra and Clonidine in the Treatment of Tics

Started Feb 2007
12 enrolled
Tic DisordersTourette Syndrome

Loss of Exclusivity

LOE Date
Sep 8, 2031
67 months away
Patent Expiry
Sep 8, 2031

Patent Records (2)

Patent #ExpiryTypeUse Code
8337890
Apr 17, 2027
Product
8623409
Sep 8, 2031
Product